Stay updated on Risankizumab in Psoriatic Arthritis Clinical Trial
Sign up to get notified when there's something new on the Risankizumab in Psoriatic Arthritis Clinical Trial page.

Latest updates to the Risankizumab in Psoriatic Arthritis Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe study record for the Phase 3 risankizumab trial in active psoriatic arthritis is now displayed, including its eligibility criteria, design, outcomes, locations, and related publications and documents.SummaryDifference100%

- Check16 days agoChange DetectedThe site footer revision changed from v3.7.2 to v3.8.0 while the page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check23 days agoChange DetectedA site-wide notice says NIH websites are transitioning terminology from “Artificial Intelligence” to “Super Intelligence.”SummaryDifference1%

- Check30 days agoChange DetectedThe ClinicalTrials.gov footer now identifies the site as revision v3.7.2 instead of v3.7.1. The page continues to display a 403 Forbidden error rather than the study record.SummaryDifference0.2%

- Check37 days agoChange DetectedThe footer revision number changes from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

- Check51 days agoChange DetectedThe page now presents the complete study record with links to key PDFs and IPD sharing information, replacing the prior error and making the KEEPsAKE 2 details accessible.SummaryDifference100%

Stay in the know with updates to Risankizumab in Psoriatic Arthritis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Risankizumab in Psoriatic Arthritis Clinical Trial page.